AMLo Biosciences

Executive Summary

AMLo Biosciences is a UK-based diagnostics company founded in 2017, dedicated to translating cancer biomarker research into prognostic and companion diagnostic tests. Its lead product, AMBLor®, is a prognostic test for early-stage melanoma designed to improve risk stratification and enable personalized patient management. By identifying patients with low-risk tumors who may safely avoid sentinel lymph node biopsy and those with high-risk tumors who require more aggressive surveillance, AMBLor® has the potential to reduce unnecessary procedures and healthcare costs. The company is also expanding its pipeline to other skin and head & neck cancers. With a strong scientific foundation and a clear unmet need in melanoma management, AMLo is positioned to address a significant market opportunity. The company is private and has not disclosed funding details, but its novel approach to tumor microenvironment biomarkers differentiates it from competitors.

Upcoming Catalysts (preview)

• Q4 2026Clinical validation data publication for AMBLor® in stage I/II melanoma70% success
• H1 2027CE marking or FDA clearance for AMBLor® prognostic test50% success
• H2 2026Strategic partnership or licensing agreement with a larger diagnostics or pharma company40% success